Short Interest in Pluri Inc. (NASDAQ:PLUR) Rises By 70.5%

Pluri Inc. (NASDAQ:PLUR) saw a significant growth in short interest in the month of August. As of August 31st, there was short interest totaling 26,450 shares, a growth of 70.5% from the August 15th total of 15,514 shares. Based on an average daily volume of 37,865 shares, the short-interest ratio is currently 0.7 days. Currently, 0.4% of the shares of the stock are short sold.

Pluri Price Performance

NASDAQ:PLUR traded down $0.03 during mid-day trading on Wednesday, reaching $1.14. The stock had a trading volume of 29,649 shares, compared to its average volume of 17,273. The stock has a 50-day simple moving average of $1.61 and a two-hundred day simple moving average of $2.47. The stock has a market capitalization of $14.08 million, a PE ratio of -0.47 and a beta of 0.68. Pluri has a 12 month low of $1.10 and a 12 month high of $4.87.

Pluri (NASDAQ:PLUR) last released its earnings results on Thursday, September 10th. The company reported ($0.54) earnings per share for the quarter, topping the consensus estimate of ($0.66) by $0.12. The business had revenue of $0.34 million for the quarter, compared to the consensus estimate of $0.66 million.

Analysts Set New Price Targets

Separately, Weiss Ratings cut shares of Pluri from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, August 26th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company currently has a consensus rating of “Sell”.

Pluri Company Profile

Pluri (NASDAQ:PLUR) is a clinical-stage biotechnology company focused on the development and manufacturing of placental-derived cell therapy products. The company’s proprietary three-dimensional microcarrier expansion platform enables large-scale, off-the-shelf production of PLX (placental expanded) cells, which are being investigated for a range of acute and chronic conditions. Pluri’s approach seeks to combine the regenerative and immunomodulatory properties of stromal cells with a scalable manufacturing process that does not require patient-specific cell harvesting.

Pluri advances its pipeline through internally funded research programs and strategic collaborations with academic institutions and government agencies.